(GEHC) GE HealthCare Technologies - Ratings and Ratios
Imaging, Ultrasound, Monitoring, Contrast, Radiopharmaceuticals
Dividends
| Dividend Yield | 0.20% |
| Yield on Cost 5y | 0.29% |
| Yield CAGR 5y | 33.33% |
| Payout Consistency | 100.0% |
| Payout Ratio | 3.0% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 30.3% |
| Value at Risk 5%th | 45.5% |
| Relative Tail Risk | -8.64% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.16 |
| Alpha | -13.95 |
| CAGR/Max DD | 0.34 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.429 |
| Beta | 1.253 |
| Beta Downside | 1.590 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.35% |
| Mean DD | 13.16% |
| Median DD | 12.89% |
Description: GEHC GE HealthCare Technologies October 14, 2025
GE HealthCare Technologies Inc. (NASDAQ: GEHC) develops, manufactures, and markets a broad portfolio of medical imaging, diagnostic, and digital-health solutions for patients in the United States, Canada, and worldwide. The company is organized into four operating segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).
The Imaging segment supplies a full range of modalities-including molecular imaging, CT, MRI, X-ray, and women’s-health systems-while AVS focuses on ultrasound, interventional imaging, and surgical visualization tools for cardiovascular, obstetric, and comprehensive care applications. PCS delivers patient-monitoring devices, cardiology diagnostics, consumables, anesthesia and maternal-infant care products, together with associated digital services. PDx provides contrast media, radiopharmaceuticals, and other diagnostic agents used in CT, MR, SPECT, and PET imaging.
GEHC was incorporated in 2022, rebranding from GE Healthcare Holding LLC in December 2022, and is headquartered in Chicago, Illinois. In FY 2023 the company reported revenue of roughly $18.4 billion, with the Imaging segment contributing about 55 % of total sales and posting an operating margin of 14 %, reflecting strong demand for high-end CT and MRI systems. Recent quarterly data show a 6 % year-over-year increase in recurring services revenue, underscoring the growing importance of subscription-based digital solutions and AI-enabled workflow tools.
Key macro drivers for GEHC include an aging global population that expands the volume of diagnostic imaging, accelerating adoption of AI and cloud-based analytics that boost equipment utilization, and reimbursement trends that favor value-based care-factors that together shape the company’s growth outlook. For a deeper, data-driven dive into GEHC’s valuation metrics and scenario analysis, consider exploring the detailed research hub on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (2.22b TTM) > 0 and > 6% of Revenue (6% = 1.21b TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -3.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 8.99% (prev 8.22%; Δ 0.77pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 913.0m <= Net Income 2.22b (YES >=105%, WARN >=100%) |
| Net Debt (6.74b) to EBITDA (3.80b) ratio: 1.77 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.18 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (457.0m) change vs 12m ago -0.44% (target <= -2.0% for YES) |
| Gross Margin 40.80% (prev 41.33%; Δ -0.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 57.86% (prev 57.77%; Δ 0.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.24 (EBITDA TTM 3.80b / Interest Expense TTM 446.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.52
| (A) 0.05 = (Total Current Assets 11.89b - Total Current Liabilities 10.07b) / Total Assets 36.13b |
| (B) 0.13 = Retained Earnings (Balance) 4.71b / Total Assets 36.13b |
| (C) 0.09 = EBIT TTM 3.23b / Avg Total Assets 34.99b |
| (D) 0.14 = Book Value of Equity 3.56b / Total Liabilities 25.91b |
| Total Rating: 1.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 63.84
| 1. Piotroski 4.0pt |
| 2. FCF Yield 1.07% |
| 3. FCF Margin 2.29% |
| 4. Debt/Equity 1.08 |
| 5. Debt/Ebitda 1.77 |
| 6. ROIC - WACC (= 3.94)% |
| 7. RoE 23.74% |
| 8. Rev. Trend 71.74% |
| 9. EPS Trend -19.01% |
What is the price of GEHC shares?
Over the past week, the price has changed by +7.85%, over one month by +16.99%, over three months by +9.39% and over the past year by +4.54%.
Is GEHC a buy, sell or hold?
- Strong Buy: 12
- Buy: 4
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GEHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 88.1 | 3.1% |
| Analysts Target Price | 88.1 | 3.1% |
| ValueRay Target Price | 86.2 | 0.9% |
GEHC Fundamental Data Overview November 26, 2025
P/E Trailing = 16.5549
P/E Forward = 16.5017
P/S = 1.8032
P/B = 3.5665
P/EG = 2.343
Beta = 1.273
Revenue TTM = 20.25b USD
EBIT TTM = 3.23b USD
EBITDA TTM = 3.80b USD
Long Term Debt = 8.28b USD (from longTermDebt, last quarter)
Short Term Debt = 2.14b USD (from shortTermDebt, last quarter)
Debt = 10.74b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.74b USD (from netDebt column, last quarter)
Enterprise Value = 43.25b USD (36.51b + Debt 10.74b - CCE 4.00b)
Interest Coverage Ratio = 7.24 (Ebit TTM 3.23b / Interest Expense TTM 446.0m)
FCF Yield = 1.07% (FCF TTM 463.0m / Enterprise Value 43.25b)
FCF Margin = 2.29% (FCF TTM 463.0m / Revenue TTM 20.25b)
Net Margin = 10.95% (Net Income TTM 2.22b / Revenue TTM 20.25b)
Gross Margin = 40.80% ((Revenue TTM 20.25b - Cost of Revenue TTM 11.98b) / Revenue TTM)
Gross Margin QoQ = 38.69% (prev 39.61%)
Tobins Q-Ratio = 1.20 (Enterprise Value 43.25b / Total Assets 36.13b)
Interest Expense / Debt = 1.03% (Interest Expense 111.0m / Debt 10.74b)
Taxrate = 27.84% (179.0m / 643.0m)
NOPAT = 2.33b (EBIT 3.23b * (1 - 27.84%))
Current Ratio = 1.18 (Total Current Assets 11.89b / Total Current Liabilities 10.07b)
Debt / Equity = 1.08 (Debt 10.74b / totalStockholderEquity, last quarter 9.99b)
Debt / EBITDA = 1.77 (Net Debt 6.74b / EBITDA 3.80b)
Debt / FCF = 14.56 (Net Debt 6.74b / FCF TTM 463.0m)
Total Stockholder Equity = 9.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.13% (Net Income 2.22b / Total Assets 36.13b)
RoE = 23.74% (Net Income TTM 2.22b / Total Stockholder Equity 9.34b)
RoCE = 18.33% (EBIT 3.23b / Capital Employed (Equity 9.34b + L.T.Debt 8.28b))
RoIC = 12.32% (NOPAT 2.33b / Invested Capital 18.90b)
WACC = 8.38% (E(36.51b)/V(47.25b) * Re(10.63%) + D(10.74b)/V(47.25b) * Rd(1.03%) * (1-Tc(0.28)))
Discount Rate = 10.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.11%
[DCF Debug] Terminal Value 68.84% ; FCFE base≈955.8m ; Y1≈927.8m ; Y5≈927.4m
Fair Price DCF = 24.09 (DCF Value 10.98b / Shares Outstanding 455.5m; 5y FCF grow -4.08% → 3.0% )
EPS Correlation: -19.01 | EPS CAGR: -16.19% | SUE: 0.31 | # QB: 0
Revenue Correlation: 71.74 | Revenue CAGR: 3.09% | SUE: 0.73 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.00 | Chg30d=-0.032 | Revisions Net=-2 | Analysts=11
EPS next Year (2026-12-31): EPS=4.91 | Chg30d=+0.000 | Revisions Net=+10 | Growth EPS=+8.6% | Growth Revenue=+4.5%
Additional Sources for GEHC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle